Your activity: 7458 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: [email protected]

Efinaconazole: Drug information

Efinaconazole: Drug information
(For additional information see "Efinaconazole: Patient drug information" and see "Efinaconazole: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Jublia
Brand Names: Canada
  • Jublia
Pharmacologic Category
  • Antifungal Agent, Topical
Dosing: Adult

Onychomycosis: Topical: Apply to affected toenail(s) once daily for 48 weeks.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Pediatric

(For additional information see "Efinaconazole: Pediatric drug information")

Onychomycosis: Children ≥6 years and Adolescents: Topical: Apply to affected toenail(s) once daily for 48 weeks.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely necessary due to low systemic absorption.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely necessary due to low systemic absorption.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, External:

Jublia: 10% (4 mL, 8 mL) [contains edetate (edta) disodium]

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, External:

Jublia: 10% (6 mL) [contains edetate (edta) disodium]

Administration: Adult

Topical: Affected toenail(s) should be clean and dry. Wait at least 10 minutes after showering, bathing, or washing the area prior to application. Gently spread the solution completely around the toenail (toenail bed, folds, hyponychium, undersurface of the toenail plate) with the attached applicator brush and let dry thoroughly; wash hands with soap and water after use.

Administration: Pediatric

Topical: Affected toenail(s) should be clean and dry. Wait at least 10 minutes after showering, bathing, or washing the area prior to application. Gently spread the solution completely around the toenail (toenail bed, folds, hyponychium, undersurface of the toenail plate) with the attached applicator brush and let dry thoroughly; wash hands with soap and water after use. For external use only (do not use orally, intravaginally, or in the eyes). Do not apply near heat or flame.

Use: Labeled Indications

Onychomycosis: Topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Ingrown nail (2%)

Local: Application site dermatitis (2%), application site vesicles (2%), application site pain (1%)

Contraindications

There are no contraindications listed in the US manufacturer’s labeling.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to efinaconazole or any component of the formulation.

Warnings/Precautions

Concerns related to adverse events:

• Local irritation: Persistent local pain, irritation, or dermatitis may develop. If this occurs, contact health care provider.

Other warnings/precautions:

• Appropriate use: For topical use only on toenail(s) and surrounding skin. Not for ophthalmologic, oral, or vaginal administration. Use of nail polish or cosmetic nail products has not been evaluated.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Small amounts of efinaconazole are absorbed systemically following topical administration. If antifungal treatment cannot be delayed until after pregnancy, topical therapy, when appropriate, is preferred over systemic treatment (Kaul 2017). Information specific to efinaconazole in pregnancy has not been located (Lipner 2015).

Breastfeeding Considerations

It is not known if efinaconazole is present in breast milk.

Small amounts of efinaconazole are absorbed systemically following topical administration. The manufacturer recommends that caution be used if administered to a breastfeeding woman.

Mechanism of Action

An azole antifungal; inhibits fungal lanosterol 14alpha-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes, resulting in fungal cell death.

Pharmacokinetics

Half-life elimination: 29.9 hours.

Pricing: US

Solution (Jublia External)

10% (per mL): $204.67

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Clenafin (JP);
  • Efinconzol-UCCMA (EG);
  • Joublia (KR);
  • Jublia (HK)


For country abbreviations used in Lexicomp (show table)

REFERENCES

  1. Jublia (efinaconazole) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2020.
  2. Jublia (efinaconazole) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; January 2020.
  3. Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. Indian Dermatol Online J. 2017;8(5):310-318. doi:10.4103/idoj.IDOJ_169_17 [PubMed 28979861]
  4. Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. Infect Drug Resist. 2015;8:163-172. [PubMed 26082652]
Topic 95757 Version 61.0